Mar 27, 2023 · Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic …

Apr 12, 2023 · UPDATE: On July 31, 2023, the Food and Drug Administration (FDA) approved dostarlimab (Jemperli) in combination with chemotherapy to treat people with endometrial …

Patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer may benefit from an option like JEMPERLI (dostarlimab-gxly) + CP. See full Indication, Safety, & PI.

Apr 22, 2021 · Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that …

JEMPERLI is an immunotherapy that may help you fight certain types of advanced or returned endometrial cancer. Discover JEMPERLI, a treatment option. Find information about dosing, …

Aug 7, 2024 · Jemperli (dostarlimab-gxly) is a cancer immunotherapy used to treat types of endometrial cancer and solid tumors. Includes Jemperli side effects, indications, and doses.

Sep 4, 2023 · Both Jemperli (dostarlimab) and Keytruda (pembrolizumab) are prescribed as second-line treatments for advanced endometrial cancer that is microsatellite instability-high …

Nov 4, 2024 · Dostarlimab, as a single agent, for dMMR recurrent or endometrial cancer: 500 mg every 3 weeks for 4 doses followed or 1,000 mg every 6 weeks via IV infusion.

Aug 2, 2024 · The US Food and Drug Administration (FDA) has approved dostarlimab (Jemperli) in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for …

Jan 21, 2025 · The label for Jemperli plus chemotherapy in the US was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. Jemperli, a …